Abstract
The angiotensin receptor neprilysin inhibitor LCZ696 (sacubitril/valsartan) reduced all-cause death and HF hospitalizations compared to enalapril. We assessed the cost-effectiveness of LCZ696 relative to enalapril in the US. Using PARADIGM-HF trial data, a two-state Markov model was developed for
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
